| Objective: To observe the clinical efficacy of modified Zhisou Powder combined with Menglustna chewable tablets in the treatment of children with cough variant asthma(CVA)(the syndrome of wind cold attacking the lung),and to explore the effects of Zhisou Powder on the lung function of children and on serum total immunoglobulin E(Ig E)and eosinophil(EOS).Methods: There were 93 children enrolled in this study,all of whom were hospitalized and outpatients in the Children’s Diagnosis and Treatment Center of the Affiliated Hospital of Changchun University of Traditional Chinese Medicine from November 2021 to November 2022.They were randomly divided into groups A,B,and C,including 35 patients in group A,two patients who fell off,and 33 patients who completed;In group B,33 cases had abscission,3 cases had abscission,and 30 cases had been completed;In group C,32 cases,2 cases dropped,30 cases completed.Group A was treated with modified Zhisou Powder,group B was treated with modified Zhisou Powder combined with Monroestner chewable tablets,and group C was treated with Monroestner chewable tablets.The total score of TCM syndromes,single syndrome score,clinical comprehensive efficacy,pulmonary function [forced vital capacity(FVC),forced expiratory volume per second(FEV1/FVC),percentage of peak expiratory flow rate(PEF%)],serum total immunoglobulin E(Ig E),peripheral blood eosinophils(EOS)and adverse reactions were compared in detail before and after treatment.SPSS26.0 Chinese version software was used for data analysis and processing.Result:1.After treatment,the total effective rate of clinical efficacy of children in group B was 90.0%,significantly higher than 70.0% in group A and 63.3% in group C,with a statistically significant difference(P(27)0.05),while there was no statistically significant difference between the total effective rate of clinical efficacy of children in group A and group C(P>0.05).2.Compared with that before treatment,the total score of TCM syndromes in the three groups were significantly reduced(P(27)0.05),with a statistically significant difference;After the treatment,the difference between the three groups was statistically significant(P(27)0.05).Further pairwise comparison showed that the total score of TCM symptoms in Group B was significantly lower than that in Group A and Group C.Compared with the scores before treatment,the scores of single symptoms in the three groups were significantly reduced(P(27)0.05).After 2 weeks of treatment,in terms of cough degree,cough frequency,runny nose,expectoration and pharyngeal itching,Group B was lower than Group A and Group C,with a statistically significant difference(P(27)0.05).There was no statistically significant difference between Group A and Group C(P>0.05).In terms of nasal congestion and sneezing,there was no statistical significance(P>0.05)in the scores of single syndrome in the three groups.3.Compared with before therapeutic regimen,FVC,FEV1/FVC and PEF% of child in the three groups improved significantly after treatment,and FVC,FEV1/FVC% and PEF% of children in Group B were(2.82 ± 0.32)L,(87.47 ± 3.67)% and(91.5 ± 3.48)% respectively,which were significantly higher than those in Group A(2.62 ± 0.31)L,(84.18 ± 3.42)%,(87.52 ± 3.11)% and Group C(2.58 ± 0.29)L,(84.73 ± 4.12)% and(88.4 ± 2.67)%,with significant differences.Meaning(P(27)0.05).4.Compared with that before therapy,the EOS level of kid in three groups after 2 weeks of treatment was significantly lower than that before treatment(P<0.05).the EOS of children in group B was 0.64±0.18(×109·L-1)is significantly lower than 0.80±0.14(×109·L-1)in group A,0.78±0.17(×109·L-1)in group C(P<0.05)。5.There was insignificant adverse reaction in group A,group B and group C(P>0.05).Conclusion:The clinical efficacy of Zhisousan plus Menglust sodium chewable tablets in the treatment of kid with cough variant asthma(wind-cold attacking lung syndrome)is better than that of Zhisousan plus or minus or Menglust sodium chewable tablets alone.According to improve cough degree,cough frequency,runny nose,expectoration and itching symptoms,the effect of Zhisousan plus Menglust sodium is better than that of the other two groups.Compared with the other two groups,the modified Zhisou powder combined with Menglust sodium chewable tablets has a more significant effect on improving lung function and can significantly reduce the level of EOS in peripheral blood.The disease recurrence rate is low and the safety is good,which is worthy of clinical promotion and use. |
PDF Full Text Request